返回 
加入收藏
HAIC-FOLFOX联合卡瑞利珠单抗用于不可切除肝细胞癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | HAIC-FOLFOX联合卡瑞利珠单抗用于不可切除肝细胞癌的临床观察 |
| TITLE： | Clinical observation of HAIC-FOLFOX combined with camrelizumab in the treatment of unresectable hepato-cellular carcinoma |
| 摘要： | 目的 探讨基于奥沙利铂和氟尿嘧啶药物组合的肝动脉灌注化疗（即HAIC-FOLFOX）联合卡瑞利珠单抗用于不可切除肝细胞癌（HCC）的有效性和安全性。方法回顾性收集2021年1月1日－2023年3月1日于辽宁省肿瘤医院住院治疗的222例不可切除HCC患者的资料，根据治疗方案的不同将其分为对照组（HAIC-FOLFOX联合索拉非尼，117例）和观察组（HAIC-FOLFOX联合卡瑞利珠单抗，105例）。比较两组患者治疗4个周期后的近期疗效指标[客观缓解率（ORR）和疾病控制率（DCR）]和远期疗效指标[中位总生存期（mOS）和1年内中位无进展生存期（mPFS）]，治疗前及治疗4个周期后的肿瘤标志物（甲胎蛋白、癌胚抗原、糖类抗原19-9）、免疫功能指标（CD3+、CD4+和CD8+T细胞亚群）水平，以及治疗期间的不良反应发生情况。结果观察组患者的ORR为55.24%，显著高于对照组的35.90%（P＜0.05），而两组患者的DCR比较差异无统计学意义（P＞0.05）；观察组患者的mOS、1年内mPFS（15.22、10.83个月）均显著长于对照组（11.34、8.04个月）（P＜0.05）。治疗4个周期后，两组患者的肿瘤标志物水平均显著低于同组治疗前，观察组患者的CD3+、CD4+T细胞比例均显著高于同组治疗前（P＜0.05）；且观察组患者的上述指标均显著优于同期对照组（P＜0.05）。观察组发生1～3级免疫相关性肺炎、毛细管增生的患者比例均显著高于对照组（P＜0.05），而两组发生1～3级发热、乏力、皮疹等不良反应的患者比例比较，差异均无统计学意义（P＞0.05）。结论相较于HAIC-FOLFOX联合索拉非尼，HAIC-FOLFOX联合卡瑞利珠单抗可显著提高不可切除HCC患者的ORR，延长mOS和1年内mPFS，有效降低肿瘤标志物水平，改善部分免疫功能指标，但会增加免疫相关不良事件的发生风险。 |
| ABSTRACT： | OBJECTIVE To investigate the efficacy and safety of hepatic arterial infusion chemotherapy based on the oxaliplatin and fluorouracil drug combination （HAIC-FOLFOX） combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma （HCC）. METHODS The data of 222 unresectable HCC patients hospitalized at Liaoning Cancer Hospital & Institute from January 1， 2021 to March 1， 2023 were retrospectively collected. Based on treatment regimens， patients were divided into a control group （HAIC-FOLFOX+sorafenib， n＝117） and an observation group （HAIC-FOLFOX+camrelizumab， n＝ 105）. Short-term efficacy indicators [objective remission rate （ORR） and disease control rate （DCR）] and long-term efficacy indicators [median overall survival （mOS） and median progression-free survival （mPFS） within one year] after 4 cycles of treatment， the levels of tumor markers （alpha fetoprotein， carcinoembryonic antigen， carbohydrate antigen 19-9）， immune function indicators （CD3+， CD4+， and CD8+ T-cell subsets） before treatment and after 4 cycles of treatment， as well as the occurrence of adverse reactions， were compared between two groups. RESULTS The ORR of the observation group was 55.24%， which was significantly higher than 35.90% of the control group （P＜0.05）； while there was no statistically significant difference in DCR between the two groups （P＞0.05）. The mOS and mPFS within 1 year of the observation group （15.33， 10.83 months） were significantly longer than the control group （11.34， 8.04 months） （P＜0.05）. After 4 cycles of treatment， tumor marker levels of the two groups were significantly lower than before treatment， and the proportions of CD3+ and CD4+ T cells were significantly higher than before treatment （P＜0.05）. Above indexes of the observation group were significantly better than the control group at the same time （P＜0.05）. The proportions of patients in the observation group who developed grade 1-3 immune-related pneumonia and capillary proliferation were significantly higher than the control group （P＜0.05）， while there were no statistically significant differences in the proportions of patients experiencing grade 1-3 adverse reactions such as fever， fatigue and rash between two groups （P＞0.05）. CONCLUSIONS Compared with HAIC-FOLFOX combined with sorafenib， HAIC-FOLFOX combined with camrelizumab can significantly improve the ORR， prolong mOS and mPFS within 1 year， effectively reduce tumor marker levels， and improve certain immune function indicators in patients with unresectable HCC， but it increases the risk of immune-related adverse events. |
| 期刊： | 2025年第36卷第22期 |
| 作者： | 祝平；卢西雅；田艳飞 |
| AUTHORS： | ZHU Ping，LU Xiya，TIAN Yanfei |
| 关键字： | 肝动脉灌注化疗；卡瑞利珠单抗；索拉非尼；不可切除肝细胞癌；有效性；安全性 |
| KEYWORDS： | hepatic arterial infusion chemotherapy； camrelizumab； sorafenib； unresectable hepatocellular carcinoma； efficacy； |
| 阅读数： | 2 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
